Reprint

Antimicrobial Therapy in Intensive Care Unit

Edited by
March 2023
260 pages
  • ISBN978-3-0365-6769-3 (Hardback)
  • ISBN978-3-0365-6768-6 (PDF)

This book is a reprint of the Special Issue Antimicrobial Therapy in Intensive Care Unit that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful information on difficult topics.

Format
  • Hardback
License
© by the authors
Keywords
Acinetobacter; pandrug-resistant; antimicrobial combinations; synergy; renal replacement therapy; Monte Carlo simulation; antibiotics; pharmacokinetics; pharmacodynamics; microbiome; probiotics; intensive care unit; dysbiosis; ventilator-associated pneumonia; extracorporeal membrane oxygenation; ECMO; antibiotics; pharmacodynamics; pharmacokinetics; critical illness; antibiotic choices; HAP; VAP; colonization; antibiotic pressure; bloodstream infection; bacteraemia; sepsis; septic shock; empirical; probabilistic antibiotics; source control; de-escalation; ICU; intensive care; antimicrobial stewardship; sepsis; COVID-19; ICU; procalcitonin; C-reactive protein; presepsin; infection; biomarker; guided antimicrobial therapy; APACHE II score; bacteremia; bloodstream infection; broth microdilution; colistin; colistin-resistant; Gram-negative; intensive care unit; mortality; SOFA score; candidemia; ICU; incidence; epidemiology; Candida species; non-albicans Candida species; fluconazole resistance; COVID-19; critically ill; beta-lactam antibiotics; pharmacokinetics; pharmacodynamics; ICU; critically ill; Acinetobacter baumannii; antibiotic optimisation; antibiotic stewardship (AMS); aspiration pneumonia; colistin; hospital-acquired pneumonia (HAP); multidrug-resistance (MDR); mortality; non-fermentative Gram-negative bacilli (GNB); polymicrobial; pneumonia resolution; ventilator-associated pneumonia (VAP); Acinetobacter; carbapenem-resistant A. baumannii (CRAb); infection control; antimicrobial agents; carbapenems; antibiotic resistance; clinical pharmacy services; antimicrobial stewardship; intensive care; pandrug-resistant; Klebsiella pneumoniae; Acinetobacter baumannii; Pseudomonas aeruginosa; salvage treatment; double carbapenem; newer β-lactam-β-lactamase inhibitors; cefiderocol; eravacycline; antimicrobial combinations; SARS-CoV-2 infection; mechanical ventilation; risk factors; blood stream infection; mortality; carbapenems; defined daily dose; antibiotics utilization; intensive care; empiric; n/a